Lanean...

Azacitidine mitigates GvHD via differential effects on the proliferation of T effectors and nTregs in vivo

Azacitidine (AzaC) mitigates Graft vs. Host Disease (GvHD) in both murine preclinical transplant models and in human clinical trials while maintaining a robust Graft vs. Leukemia (GvL) effect. Previous studies have failed to investigate the role of natural Tregs on the mitigation of GvHD by AzaC; in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunol
Egile Nagusiak: Cooper, Matthew L., Choi, Jaebok, Karpova, Darja, Vij, Kiran, Ritchey, Julie, Schroeder, Mark A., DiPersio, John F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5541679/
https://ncbi.nlm.nih.gov/pubmed/28330901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1502399
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!